研究人员正在探索新的细胞疗法和分子,以阻止1型糖尿病,旨在恢复天然胰岛素生产。 Researchers are exploring new cell therapies and molecules to halt Type 1 diabetes, aiming to restore natural insulin production.

约翰·霍普金斯工程师正在为1型糖尿病开发基于细胞的免疫疗法,目的是防止免疫系统攻击胰岛素生产细胞。 Johns Hopkins engineers are developing cell-based immunotherapies for Type 1 diabetes, aiming to prevent the immune system from attacking insulin-producing cells in the pancreas. 这种方法利用可生物降解的纳米粒子将基因改造的细胞输送到肝脏的免疫细胞,有可能阻止自动免疫反应和恢复适当的胰岛素生产。 This approach uses biodegradable nanoparticles to deliver genetically engineered cells to the liver’s immune cells, potentially stopping the autoimmune response and restoring proper insulin production. 与此同时，西奈山的研究人员发现，harmine 这种分子可以刺激 β 细胞复制，而 Sana Biotechnology 正在测试一种无需免疫抑制治疗的新型胰岛细胞移植方法。 Meanwhile, researchers at Mount Sinai have found that harmine, a molecule, can stimulate beta cell replication, while Sana Biotechnology is testing a new islet cell transplantation method without immunosuppressive therapy. 这些创新可以显著改善糖尿病的治疗。 These innovations could significantly improve treatment for diabetes.